1. Market Research
  2. > Pharmaceutical Market Trends
  3. > India Pharmaceuticals and Healthcare Report Q4 2016

India Pharmaceuticals and Healthcare Report Q4 2016

  • August 2016
  • -
  • Business Monitor International
  • -
  • 120 pages

Includes 3 FREE quarterly updates

BMI View: India's pharmaceutical market will continue to see more biosimilar products being launched bydomestic drugmakers. Developing such products is a business necessity for Indian firms to maintainrevenue growth as commoditisation limits the commercial opportunities from simple chemical molecules.This dovetails with their improving scientific and manufacturing ability, posing a pertinent threat tooriginator pharmaceutical firms that have product portfolios dominated by biologics.Headline Expenditure ProjectionsPharmaceuticals: INR1,066bn (USD17bn) in 2015 to INR1,191bn (17bn) by 2016; +11.8% in localcurrency terms and 5.1% in US dollar terms. Forecast unchanged from last quarter.Healthcare: INR6,695bn (USD104bn) in 2015 to INR7,561bn (USD111bn) by 2016; +12.9% in localcurrency terms and 6.2% in US dollar terms. Forecast revised upwards from last quarter.

Table Of Contents

India Pharmaceuticals and Healthcare Report Q4 2016
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (India 2014-2020) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (India 2012-2020) 13
Healthcare Market Forecast 14
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (India 2012-2020) 16
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (India 2012-2020) 17
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (India 2012-2020) 18
Prescription Drug Market Forecast 19
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (India 2012-2020) 21
Patented Drug Market Forecast 22
Table: Selected Patent Developments Affecting Drugmakers 23
Table: Patented Drug Market Indicators, Historical Data And Forecasts (India 2012-2020) 25
Generic Drug Market Forecast 26
Table: Generic Drug Market Indicators, Historical Data And Forecasts (India 2012-2020) 27
OTC Medicine Market Forecast 28
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (India 2012-2020) 29
Pharmaceutical Trade Forecast 30
Table: Pharmaceutical Trade Data And Forecasts (India 2014-2020) 32
Table: Pharmaceutical Trade Data And Forecasts local currency (India 2014-2020) 32
Industry Risk/Reward Index 33
Asia Pacific Risk/Reward Index - Q4 2016 33
India Risk/Reward Index 40
Rewards 40
Risks 40
Regulatory Review 42
Intellectual Property Issues 46
Table: History Of The Indian Patent System 47
Table: Special 301 Submission: Issues Raised For India 48
Table: A Series Of Setbacks For Innovative Pharmaceutical Firms 48
Pricing Regime 52
Market Overview 57
Healthcare Sector 57
Table: Healthcare Resources (India 2010-2015) 60
Table: Healthcare Personnel (India 2010-2015) 60
Table: Healthcare Activity (India 2010-2015) 61
Research and Development 61
Clinical Trials 63
Epidemiology 65
Table: Estimated Number Of New Cases Of Cancer In India 67
Competitive Landscape 68
Research-Based Industry 68
Table: Ordinary Members Of OPPI 68
Table: Multinational Market Activity 69
Pharmaceutical Distribution 72
Pharmaceutical Retail Sector 72
Company Profile 74
Aurobindo Pharmaceutical 74
Cipla 77
Dr Reddy's Laboratories 81
GlaxoSmithKline 85
Merck and Co 90
Novartis 93
Pfizer 97
Sanofi India 102
Sun Pharmaceutical 106
Demographic Forecast 109
Table: Population Headline Indicators (India 1990-2025) 110
Table: Key Population Ratios (India 1990-2025) 110
Table: Urban/Rural Population and Life Expectancy (India 1990-2025) 111
Table: Population By Age Group (India 1990-2025) 111
Table: Population By Age Group % (India 1990-2025) 112
Glossary 114
Methodology 116
Pharmaceutical Expenditure Forecast Model 116
Healthcare Expenditure Forecast Model 116
Notes On Methodology 117
Risk/Reward Index Methodology 118
Index Overview 119
Table: Pharmaceutical Risk/Reward Index Indicators 119
Indicator Weightings 120

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025 Summary Atrial fibrillation (AF) is the most common cardiac arrhythmia and is a heart condition that causes an irregula ...

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025 Summary Venous thromboembolism (VTE) is a disease that includes a myriad of life-threatening disorders ranging from ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.